{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:26:52Z","timestamp":1794378412522,"version":"4.9.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","funder":[{"name":"Mark and Jane Gibson Endowment Fund"},{"name":"Shandong Province Government-Sponsored Overseas Study Program for the Non-Educational Sector"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:p>Folate receptor alpha (FR\u03b1) is highly expressed in tubo-ovarian high-grade serous carcinoma (HGSC), but its expression in serous tubal intraepithelial carcinoma (STIC) and earlier tubal lesions has not been systematically characterized. We evaluated FR\u03b1 expression across the spectrum of fallopian tube lesions and assessed its potential as an adjunctive diagnostic biomarker.<\/jats:p>\n                  <jats:p>Immunohistochemistry was performed on 408 tubal epithelial samples from 262 patients, including 52 normal fallopian tube samples, 110 secretory cell expansions (SCE), 88 secretory cell outgrowths (SCOUT), 72 serous tubal intraepithelial lesions (STIL), and 56 STICs. An additional 30 HGSCs were included for comparison. FR\u03b1 expression was assessed using the percentage score \u22652+ (PS2+) system. Associations with germline BRCA status and age were evaluated.<\/jats:p>\n                  <jats:p>FR\u03b1 expression was detectable in normal fallopian tube epithelium but usually below the high-expression threshold. In contrast, expression was increased in STIC and HGSC, with high PS2+ scores in 73.2% and 76.7% of cases, respectively. Earlier tubal lesions showed predominantly low or negative\/very low expression. No significant difference in FR\u03b1 expression was observed between STIC and HGSC. BRCA-mutated STIC and HGSC showed higher FR\u03b1 expression than their BRCA nonmutated counterparts, whereas earlier lesions showed no such association. In normal fallopian tube epithelium, FR\u03b1 expression decreased with age.<\/jats:p>\n                  <jats:p>These findings demonstrate that FR\u03b1 upregulation is established at the STIC stage and maintained in invasive HGSC. Diffuse high-level expression is uncommon in STIL and earlier lesions, suggesting that FR\u03b1 may serve as an adjunct biomarker for distinguishing STIC from morphologically overlapping lesions. When interpreted in conjunction with morphology, p53, and Ki-67, FR\u03b1 may improve diagnostic confidence along the STIL-to-STIC spectrum. The early and sustained upregulation of FR\u03b1 in STIC also raises interesting questions regarding the timing of FR\u03b1-targeted interventions.<\/jats:p>","DOI":"10.1097\/pas.0000000000002612","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:00:50Z","timestamp":1788282050000},"page":"1470-1478","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Folate Receptor Alpha Expression Across the Spectrum of Serous Tubal Lesions"],"prefix":"10.1097","volume":"50","author":[{"given":"Yan","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rujia","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Henan Provincial People\u2019s Hospital, Zhengzhou University People\u2019s Hospital, Henan University People\u2019s Hospital, Zhengzhou, Henan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6550-5179","authenticated-orcid":false,"given":"Zeng","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University"},{"name":"Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong, China"},{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijiao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Liu","sequence":"additional","affiliation":[{"name":"Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Ruhul","family":"Quddus","sequence":"additional","affiliation":[{"name":"Department of Pathology, Mount Sinai Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwole","family":"Fadare","sequence":"additional","affiliation":[{"name":"Department of Pathology, Women and Infants Hospital, The Warren Alpert Medical School of Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanthi","family":"Lea","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Department of Pathology, UC San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beihua","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong, China"},{"name":"Department of Pathology"},{"name":"Department of Pathology, UC San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"R1-20261111","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","article-title":"Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features","volume":"460","author":"Prat","year":"2012","journal-title":"Virchows Arch"},{"key":"R2-20261111","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/ijms20040952","article-title":"High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints","volume":"20","author":"Lisio","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R3-20261111","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","article-title":"Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship","volume":"31","author":"Kindelberger","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R4-20261111","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","article-title":"Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models","volume":"24","author":"Perets","year":"2013","journal-title":"Cancer Cell"},{"key":"R5-20261111","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nat Commun"},{"key":"R6-20261111","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/PGP.0b013e31824cbeb4","article-title":"Ki-67 labeling index as an adjunct in the diagnosis of serous tubal intraepithelial carcinoma","volume":"31","author":"Kuhn","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"R7-20261111","doi-asserted-by":"crossref","first-page":"pky061","DOI":"10.1093\/jncics\/pky061","article-title":"Population frequency of serous tubal intraepithelial carcinoma (STIC) in clinical practice using SEE-FIM protocol","volume":"2","author":"Samimi","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"R8-20261111","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/1471-0528.14543","article-title":"Serous tubal intraepithelial carcinomas associated with high-grade serous ovarian carcinomas: a systematic review","volume":"124","author":"Chen","year":"2017","journal-title":"BJOG"},{"key":"R9-20261111","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/path.2739","article-title":"Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube","volume":"222","author":"Chen","year":"2010","journal-title":"J Pathol"},{"key":"R10-20261111","first-page":"2082","article-title":"Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis","volume":"7","author":"Wang","year":"2015","journal-title":"Am J Transl Res"},{"key":"R11-20261111","doi-asserted-by":"crossref","first-page":"126295","DOI":"10.1155\/2010\/126295","article-title":"Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics","volume":"2010","author":"Gross","year":"2010","journal-title":"J Oncol"},{"key":"R12-20261111","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3892\/br.2017.955","article-title":"The conceptual advances of carcinogenic sequence model in high-grade serous ovarian cancer","volume":"7","author":"Kobayashi","year":"2017","journal-title":"Biomed Rep"},{"key":"R13-20261111","first-page":"1295","article-title":"Ovarian serous carcinogenesis from tubal secretory cells","volume":"30","author":"Zhang","year":"2015","journal-title":"Histol Histopathol"},{"key":"R14-20261111","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/annonc\/mdv250","article-title":"Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments","volume":"26","author":"Ledermann","year":"2015","journal-title":"Ann Oncol"},{"key":"R15-20261111","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ijc.21712","article-title":"The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?","volume":"119","author":"Kelemen","year":"2006","journal-title":"Int J Cancer"},{"key":"R16-20261111","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.addr.2004.01.001","article-title":"Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy","volume":"56","author":"Elnakat","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"key":"R17-20261111","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/PGP.0b013e3182774562","article-title":"Expression of folate receptor-alpha (FRA) in gynecologic malignancies and its relationship to the tumor type","volume":"32","author":"O\u2019Shannessy","year":"2013","journal-title":"Int J Gynecol Pathol"},{"key":"R18-20261111","doi-asserted-by":"crossref","first-page":"100917","DOI":"10.1016\/j.currproblcancer.2022.100917","article-title":"Folate receptor as a biomarker and therapeutic target in solid tumors","volume":"47","author":"Young","year":"2023","journal-title":"Curr Probl Cancer"},{"key":"R19-20261111","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in fralpha-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"R20-20261111","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"key":"R21-20261111","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1097\/PAS.0b013e31822f58bc","article-title":"Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study","volume":"35","author":"Visvanathan","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"R22-20261111","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/PGP.0b013e31823b8831","article-title":"Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma","volume":"31","author":"Vang","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"R23-20261111","first-page":"3815","article-title":"Loss of tubal ciliated cells as a risk for \u201covarian\u201d or pelvic serous carcinoma","volume":"10","author":"Tao","year":"2020","journal-title":"Am J Cancer Res"},{"key":"R24-20261111","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ygyno.2013.09.018","article-title":"Secretory cell expansion with aging: risk for pelvic serous carcinogenesis","volume":"131","author":"Li","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R25-20261111","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1158\/1940-6207.CAPR-18-0009","article-title":"Fallopian tube lesions in women at high risk for ovarian cancer: a multicenter study","volume":"11","author":"Visvanathan","year":"2018","journal-title":"Cancer Prev Res (Phila)"},{"key":"R26-20261111","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","article-title":"Characterization of folate receptor alpha (FRalpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FRalpha-targeting antibody-drug conjugate mirvetuximab soravtansine","volume":"147","author":"Martin","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R27-20261111","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"key":"R28-20261111","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.5858\/arpa.2023-0149-OA","article-title":"Development of an FRalpha companion diagnostic immunohistochemical assay for mirvetuximab soravtansine","volume":"148","author":"James","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"R29-20261111","first-page":"6708","article-title":"Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis","volume":"52","author":"Weitman","year":"1992","journal-title":"Cancer Res"},{"key":"R30-20261111","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1023\/A:1027313502270","article-title":"Folate receptors in malignant and benign tissues of human female genital tract","volume":"17","author":"Holm","year":"1997","journal-title":"Biosci Rep"},{"key":"R31-20261111","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13048-015-0156-0","article-title":"Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers","volume":"8","author":"O\u2019Shannessy","year":"2015","journal-title":"J Ovarian Res"},{"key":"R32-20261111","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41467-017-01217-9","article-title":"Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma","volume":"8","author":"Ducie","year":"2017","journal-title":"Nat Commun"},{"key":"R33-20261111","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"dagger Ann Oncol"},{"key":"R34-20261111","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/2159-8290.CD-16-0607","article-title":"Genomics of ovarian cancer progression reveals diverse metastatic trajectories including intraepithelial metastasis to the fallopian tube","volume":"6","author":"Eckert","year":"2016","journal-title":"Cancer Discov"},{"key":"R35-20261111","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.5858\/arpa.2017-0231-RA","article-title":"Serous tubal intraepithelial carcinoma or not? Metastases to fallopian tube mucosa can masquerade as in situ lesions","volume":"141","author":"Singh","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"R36-20261111","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3121\/cmr.2007.702","article-title":"Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer","volume":"5","author":"Crum","year":"2007","journal-title":"Clin Med Res"},{"key":"R37-20261111","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube","volume":"211","author":"Lee","year":"2007","journal-title":"J Pathol"},{"key":"R38-20261111","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/bjc.2014.567","article-title":"Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study","volume":"111","author":"Kobel","year":"2014","journal-title":"Br J Cancer"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:00:27Z","timestamp":1794376827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002612"}},"subtitle":["An Adjunct Biomarker for Distinguishing Serous Tubal Intraepithelial Carcinoma From Serous Tubal Intraepithelial Lesions"],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002612","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"2026-06-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}